BioMarin announces updated strategy for Roctavian to focus on US, Germany & Italy
BioMarin Pharmaceutical Inc. announced it will make changes to its Roctavian business to focus commercial operations on three markets, the United States, Germany and Italy, where the medicine is approved and reimbursed as a treatment for severe haemophilia …